Study guide
4.1 Alcohol Use Screening & Brief Intervention
ABFM Family Medicine Certification Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making
1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care
2 Chapter 2: Healthcare Systems, Practice Management & Quality
2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination
3 Chapter 3: Ethics, Law, Biostatistics & Health Equity
3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism
4 Chapter 4: Lifestyle Counseling & Behavior Change
4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling
5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention
5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling
6 Chapter 6: Routine Adult Immunizations
6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise
7 Chapter 7: Pediatric Health Maintenance & Surveillance
7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride
8 Chapter 8: Behavioral Health & Safety Screening
8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling
9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic
9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening
10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic
10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling
11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate
11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making
12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception
12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C
13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care
13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam
14 Chapter 14: Emergent Cardiovascular Conditions
14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies
15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises
15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management
16 Chapter 16: Vascular & Thromboembolic Emergencies
16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion
17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness
17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion
18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies
18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies
19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies
19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice
20 Chapter 20: Acute Pulmonary & Airway Emergencies
20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction
21 Chapter 21: Acute Traumatic Injuries & Wound Care
21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites
22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies
22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises
23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies
23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection
24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies
24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis
25 Chapter 25: Hematologic, Urologic & Dental Emergencies
25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma
26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies
26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia
27 Chapter 27: Acute Head, Neck & Neurologic Symptoms
27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring
28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms
28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis
29 Chapter 29: Acute Upper Respiratory Tract Infections
29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion
30 Chapter 30: Acute Lower Respiratory Infections & Cough
30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia
31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions
31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation
32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms
32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation
33 Chapter 33: Acute Upper Gastrointestinal Conditions
33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness
34 Chapter 34: Acute Lower Gastrointestinal Conditions
34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani
35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders
35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes
36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders
36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis
37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions
37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation
38 Chapter 38: Acute Infectious Dermatoses
38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum
39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses
39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma
40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries
40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains
41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries
41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes
42 Chapter 42: Acute Ambulatory Fractures & Dislocations
42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation
43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls
43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients
44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain
44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies
45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions
45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction
46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions
46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation
47 Chapter 47: Acute Women's Health & Early Pregnancy Care
47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder
48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination
48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis
49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections
49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses
50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia
50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT
51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases
51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy
52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD
52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria
53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus
53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance
54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases
54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition
55 Chapter 55: Chronic Endocrine Disorders
55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders
56 Chapter 56: Chronic Kidney Disease & Venous Disorders
56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD
57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases
57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy
58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care
58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders
59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders
59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome
60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders
60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care
61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders
61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness
62 Chapter 62: Chronic Psychiatric Disorders
62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder
63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions
63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating
64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation
64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy
65 Chapter 65: Chronic Dermatologic Conditions
65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus
66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care
66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control
67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit
67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit
4.1 Alcohol Use Screening & Brief Intervention
Key Takeaways Explain This Topic AI
The USPSTF recommends screening for unhealthy alcohol use in all primary care adults aged 18 and older, including pregnant individuals (Grade B), utilizing validated instruments such as the AUDIT, AUDIT-C, or single-item screening question.
Risky drinking thresholds established by the NIAAA are defined as >14 standard drinks per week or >4 drinks on any single day for men, and >7 standard drinks per week or >3 drinks on any single day for women and all adults aged 65 and older. A standard US drink contains 14 grams (0.6 fluid ounces) of pure ethanol.
The SBIRT framework integrates universal screening with the FRAMES brief motivational intervention model (Feedback, Responsibility, Advice, Menu of options, Empathy, Self-efficacy) and OARS core communication techniques (Open questions, Affirmations, Reflections, Summaries).
First-line FDA-approved pharmacotherapies for moderate-to-severe Alcohol Use Disorder (AUD) are oral naltrexone (50 mg daily, reducing cravings and heavy drinking days; contraindicated in acute hepatitis, liver failure, or concurrent opioid therapy) and acamprosate (666 mg TID, restoring glutamate/GABA balance, preferred in liver impairment; contraindicated if CrCl < 30 mL/min).
Objective biomarkers of chronic heavy alcohol consumption include an AST:ALT ratio > 2:1 (reflecting mitochondrial AST release and hepatic pyridoxal 5'-phosphate depletion), elevated serum GGT (enzyme induction, normalizes in 2-4 weeks), macrocytosis (MCV > 100 fL, normalizes in 2-4 months), and urine ethyl glucuronide (EtG, window of 48-80 hours).
Last updated: September 2026
Epidemiology and Clinical Scope of Unhealthy Alcohol Use
Unhealthy alcohol use is one of the leading preventable causes of morbidity, mortality, and disability in the United States, contributing to more than 140,000 deaths annually and accounting for substantial healthcare expenditures. The spectrum of unhealthy alcohol use encompasses a continuum extending from risky or hazardous drinking (drinking patterns that elevate the risk of future physical or mental health consequences) to harmful drinking (patterns causing established medical or psychosocial injury) and formal Alcohol Use Disorder (AUD) as defined by the DSM-5-TR.
In outpatient primary care, the vast majority of patients with unhealthy drinking do not carry an established diagnosis of severe alcohol dependence; rather, they present with risky drinking that silently exacerbates chronic medical disorders—including essential hypertension, cardiac arrhythmias (notably atrial fibrillation), gastroesophageal reflux disease, nonalcoholic/metabolic fatty liver disease, insomnia, depression, and bone demineralization. Consequently, systematic primary care screening and early brief intervention represent some of the highest-value preventive clinical services in ambulatory medicine.
Screening Guidelines & Validated Screening Instruments
The U.S. Preventive Services Task Force (USPSTF) assigns a Grade B recommendation for screening all adults aged 18 and older—including pregnant individuals—for unhealthy alcohol use in primary care settings, coupled with providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions. The American Academy of Family Physicians (AAFP) fully endorses this recommendation.
Clinicians should not rely on unstructured clinical intuition or general questioning, which misses up to 50% to 75% of patients with unhealthy drinking. Instead, validated screening instruments must be integrated into routine intake workflows:
1. The Single-Question Screening Test
Prompt : "How many times in the past year have you had 5 or more drinks in a day (for men) or 4 or more drinks in a day (for women)?"
Interpretation : Any response of one or more times ( ≥ 1 \ge 1 ≥ 1 ) constitutes a positive screen, yielding a sensitivity of 80% to 88% and a specificity of 74% to 88% for unhealthy alcohol use.
Clinical Utility : Rapid, highly pragmatic, and effortlessly incorporated into nursing vital signs or electronic health record (EHR) pre-visit questionnaires.
2. The AUDIT-C (Alcohol Use Disorders Identification Test – Consumption)
The AUDIT-C comprises the first three consumption-specific questions of the full 10-item World Health Organization AUDIT questionnaire. Each question is scored from 0 to 4, yielding a total score from 0 to 12:
How often do you have a drink containing alcohol? (0 = Never; 1 = Monthly or less; 2 = 2–4 times/month; 3 = 2–3 times/week; 4 = 4+ times/week)
How many drinks containing alcohol do you have on a typical day when you are drinking? (0 = 1 or 2; 1 = 3 or 4; 2 = 5 or 6; 3 = 7 to 9; 4 = 10 or more)
How often do you have 6 or more drinks on one occasion? (0 = Never; 1 = Less than monthly; 2 = Monthly; 3 = Weekly; 4 = Daily or almost daily)
Diagnostic Cutoffs :
Men : A score of ≥ 4 \ge 4 ≥ 4 points is considered positive for unhealthy alcohol use (sensitivity ~86%, specificity ~72%).
Women : A score of ≥ 3 \ge 3 ≥ 3 points is considered positive (sensitivity ~88%, specificity ~80%).
A higher score (e.g., ≥ 7 – 8 \ge 7–8 ≥ 7–8 points) strongly correlates with moderate-to-severe Alcohol Use Disorder.
3. The Full 10-Item AUDIT
The gold-standard comprehensive screening questionnaire evaluates alcohol consumption (Questions 1–3), drinking behaviors and dependence symptoms (Questions 4–6), and alcohol-related adverse consequences (Questions 7–10). Scored from 0 to 40:
0–7 points : Low risk (provide positive reinforcement and general health education).
8–15 points : Hazardous or harmful alcohol use (provide brief behavioral intervention and structured follow-up).
16–19 points : Harmful alcohol use / intermediate risk (provide brief intervention, discuss pharmacotherapy, and schedule close medical monitoring).
20–40 points : Severe risk / Alcohol Use Disorder (provide brief intervention, medical evaluation for detoxification/pharmacotherapy, and direct referral to specialized addiction treatment).
4. The CAGE Questionnaire
The historic CAGE questionnaire consists of 4 mnemonic questions:
Have you ever felt you should C ut down on your drinking?
Have people A nnoyed you by criticizing your drinking?
Have you ever felt bad or G uilty about your drinking?
Have you ever had a drink first thing in the morning to steady your nerves or get rid of a hangover ( E ye-opener)?
Board Exam Pearl on CAGE : A score of ≥ 2 \ge 2 ≥ 2 positive responses has high specificity (~90%) for established, severe alcohol dependence. However, CAGE has poor sensitivity (<40–50%) for detecting early, at-risk, or hazardous drinking because it queries lifetime behavioral guilt rather than current volume or consumption patterns. Modern guidelines favor the AUDIT-C or Single-Question Screener for universal primary care screening.
Screening Instrument Comparison
Screening Tool Number of Items Positive Cutoff Target Identified Primary Clinical Strengths
Single-Item Screener 1 question ≥ 1 \ge 1 ≥ 1 episode of heavy drinking in past year Unhealthy alcohol use (binge/at-risk) Ultra-rapid; ideal for routine triage intake
AUDIT-C 3 questions ≥ 4 \ge 4 ≥ 4 (men), ≥ 3 \ge 3 ≥ 3 (women) Spectrum of unhealthy drinking High sensitivity and specificity; quantifies consumption
Full AUDIT 10 questions ≥ 8 \ge 8 ≥ 8 points Hazardous drinking & AUD Detailed risk stratification; guides intensity of intervention
CAGE 4 questions ≥ 2 \ge 2 ≥ 2 positive responses Severe AUD / physical dependence High specificity for late-stage dependence; poor for early prevention
Standard Drink Quantification & NIAAA Risky Drinking Limits
Accurate screening requires precise clinical quantification of ethanol intake. In the United States, one standard drink contains approximately 14 grams (0.6 fluid ounces or 1.2 tablespoons) of pure ethanol .
Standard Drink Equivalents
Regular Beer : 12 fluid ounces (355 mL) at ~5% alcohol by volume (ABV).
Craft Beer / Malt Liquor : 8 to 9 fluid ounces at ~7% ABV (a 16 oz craft IPA may equal 2 to 2.5 standard drinks).
Table Wine : 5 fluid ounces (148 mL) at ~12% ABV (a standard 750 mL bottle contains ~5 standard drinks).
Fortified Wine (sherry, port): 3 to 4 fluid ounces at ~17% ABV.
Distilled Spirits (80-proof) (vodka, whiskey, gin, rum, tequila): 1.5 fluid ounces (44 mL, a single "shot") at 40% ABV.
NIAAA Definitions of Risky Drinking Patterns
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines maximum drinking limits that minimize alcohol-attributable health harm in non-pregnant adults:
Men Aged 18 to 64 :
Daily limit : No more than 4 standard drinks on any single day, AND
Weekly limit : No more than 14 standard drinks per week.
Women (All Ages) and Men Aged ≥ 65 \ge 65 ≥ 65 :
Daily limit : No more than 3 standard drinks on any single day, AND
Weekly limit : No more than 7 standard drinks per week.
Physiological rationale for lower limits in women : Lower gastric alcohol dehydrogenase (ADH) activity, higher proportion of body fat, and lower total body water distribution volume result in significantly higher blood alcohol concentrations (BAC) per gram of ethanol consumed compared to men.
Physiological rationale in older adults : Age-related reduction in total body water, decreased hepatic microsomal clearance, enhanced central nervous system sensitivity, and higher prevalence of interacting medications (antihypertensives, sedatives, NSAIDs).
Binge Drinking : A pattern of drinking that elevates blood alcohol concentration (BAC) to ≥ 0.08 g/dL \ge 0.08\text{ g/dL} ≥ 0.08 g/dL ( ≥ 17.4 mmol/L \ge 17.4\text{ mmol/L} ≥ 17.4 mmol/L ). This typically corresponds to consuming ≥ 5 \ge 5 ≥ 5 standard drinks for men or ≥ 4 \ge 4 ≥ 4 standard drinks for women within approximately 2 hours.
Heavy Alcohol Use : Binge drinking on 5 or more days in the past 30 days.
The SBIRT Protocol: Screening, Brief Intervention & Referral to Treatment
SBIRT is an evidence-based, comprehensive public health model designed for early identification and intervention in healthcare settings:
Screening (S) : Universal, systematic screening of all patients using validated tools (e.g., AUDIT-C) to rapidly identify individuals engaging in unhealthy drinking.
Brief Intervention (BI) : A short, structured dialogue (typically 5 to 15 minutes) utilizing motivational interviewing principles to raise the patient's awareness of their drinking risks and elicit internal motivation to modify behavior.
Referral to Treatment (RT) : Facilitating proactive, warm-handoff referrals to specialty addiction medicine, outpatient behavioral therapy, medically supervised detoxification, or peer recovery groups for patients meeting criteria for moderate-to-severe Alcohol Use Disorder.
Motivational Interviewing (MI) Principles & Techniques
Motivational interviewing is a collaborative, goal-oriented communication method designed to strengthen personal motivation for and commitment to a specific behavioral goal by eliciting and exploring the person's own reasons for change within an atmosphere of acceptance and compassion.
The Spirit of MI: The PACE Model
Partnership : Collaborative alliance between two equals; avoiding the "expert trap" or authoritarian lecturing.
Acceptance : Unconditional positive regard, honoring patient autonomy, empathy, and affirmation.
Compassion : Actively prioritizing the patient's well-being and best interests.
Evocation : Drawing out the patient's own ideas, values, and motivations for change rather than imposing external advice.
Core Micro-Skills: The OARS Framework
Open-Ended Questions : Questions that cannot be answered with a simple "yes" or "no," encouraging reflection ( "What role does alcohol play in your routine when winding down after a stressful shift?" ).
Affirmations : Explicitly recognizing the patient's strengths, honesty, and past successes ( "It takes real honesty and courage to share your drinking patterns with me today." ).
Reflective Listening : Stating back the emotional or cognitive essence of what the patient expressed. Reflections can be simple, amplified, or double-sided to illuminate internal ambivalence ( "On one hand, drinking helps numb the anxiety you feel in the evenings; on the other hand, you are worried about how it impacts your liver enzymes and your presence with your children." ).
Summaries : Synthesizing the discussion to consolidate key points, highlight change talk, and transition toward planning ( "Let me make sure I've captured everything: you value your health and want to avoid liver disease, but alcohol has become your default coping tool for work stress. You'd like to explore alternative ways to relax that don't involve drinking. Is that accurate?" ).
The Readiness Ruler
When assessing readiness to change, clinicians utilize a 1-to-10 visual or verbal scale assessing Importance ( "How important is it for you to cut down?" ) and Confidence ( "How confident are you that you could succeed?" ):
Evoking Change Talk : If a patient chooses a 4 on a scale of 1 to 10, the critical MI response is: "Why did you choose a 4 and not a 1 or a 2?" This forces the patient to articulate their own internal reasons for wanting to change.
Identifying Action Steps : Follow up with: "What would it take for you to move from a 4 to a 6 or a 7?" This prompts the patient to problem-solve practical solutions.
The FRAMES Brief Intervention Model
The FRAMES model provides a time-tested, structured framework for delivering brief clinical interventions in primary care encounters lasting under 10 minutes:
Feedback (F) : Deliver objective, personalized feedback regarding the patient's reported consumption, calculated screening scores, and associated physical findings or laboratory abnormalities ( "Based on the screening questionnaire, you are consuming 22 drinks per week, which places your health in the hazardous drinking category and explains the elevation in your liver enzymes." ).
Responsibility (R) : Emphasize that the decision to change, moderate, or stop drinking rests entirely with the patient ( "No one can force you to change how you drink; what you decide to do with this information is completely up to you." ).
Advice (A) : Provide a clear, explicit, non-judgmental clinical recommendation to reduce or eliminate drinking ( "As your physician, my strong medical recommendation is that you cut back your drinking to below the recommended limits of no more than 3 drinks on any day and no more than 7 per week, or consider stopping entirely." ).
Menu of Options (M) : Offer a diverse selection of practical strategies rather than a single prescriptive mandate (e.g., designating alcohol-free weekdays, alternating alcoholic drinks with sparkling water, using a smartphone tracking app, initiating pharmacotherapy, or attending a SMART Recovery or AA meeting).
Empathy (E) : Maintain a warm, supportive, non-confrontational, and reflective conversational tone throughout the interaction.
Self-Efficacy (S) : Foster optimism and reinforce the patient's confidence and capability to succeed ( "You have successfully navigated significant workplace challenges in the past, and I am confident that with a clear plan, you can take control of your drinking." ).
Diagnostic Criteria for Alcohol Use Disorder (DSM-5-TR)
Alcohol Use Disorder is diagnosed when a patient demonstrates a problematic pattern of alcohol use leading to clinically significant impairment or distress, manifested by at least 2 of the following 11 criteria occurring within a 12-month period :
Impaired Control
Alcohol is often taken in larger amounts or over a longer period than was intended.
Persistent desire or unsuccessful efforts to cut down or control alcohol use.
A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or recover from its effects.
Craving , or a strong desire or urge to use alcohol.
Social & Occupational Impairment
Recurrent alcohol use resulting in a failure to fulfill major role obligations at work, school, or home.
Continued alcohol use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of alcohol.
Important social, occupational, or recreational activities are given up or reduced because of alcohol use.
Risky Use
Recurrent alcohol use in situations in which it is physically hazardous (e.g., driving an automobile, operating machinery).
Alcohol use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by alcohol.
Pharmacological Criteria
Tolerance , defined by either: (a) a need for markedly increased amounts of alcohol to achieve intoxication or desired effect; or (b) a markedly diminished effect with continued use of the same amount of alcohol.
Withdrawal , manifested by either: (a) the characteristic withdrawal syndrome for alcohol; or (b) alcohol (or a closely related substance, such as a benzodiazepine) is taken to relieve or avoid withdrawal symptoms.
Severity Staging
Mild AUD : Presence of 2 to 3 criteria.
Moderate AUD : Presence of 4 to 5 criteria.
Severe AUD : Presence of 6 or more criteria.
Pharmacotherapy for Alcohol Use Disorder
Pharmacotherapy is substantially underutilized in primary care, with fewer than 10% of eligible AUD patients receiving evidence-based medications. The American Psychiatric Association (APA) and the Department of Veterans Affairs / Department of Defense (VA/DoD) guidelines recommend offering pharmacotherapy to all patients with moderate-to-severe AUD who desire to reduce consumption or achieve abstinence.
Master Table of Pharmacotherapies for Alcohol Use Disorder
Medication FDA Status Mechanism of Action Dosing & Administration Clinical Indications & Strengths Contraindications & Red Flags
Oral Naltrexone (ReVia) FDA-Approved (First-Line) Competitive μ \mu μ -opioid receptor antagonist; blocks endogenous endorphin reward pathways in ventral tegmental area / nucleus accumbens 50 mg PO once daily (can initiate at 25 mg daily for 3–4 days to minimize nausea) First-line for moderate-to-severe AUD. Reduces cravings and heavy drinking days. Can be initiated while the patient is still actively drinking (harm reduction). Contraindicated in acute hepatitis, hepatic failure (decompensated cirrhosis), and concurrent opioid therapy . Must be opioid-free for ≥ 7 – 14 \ge 7–14 ≥ 7–14 days prior to initiation to avoid severe precipitated opioid withdrawal. Check baseline LFTs.
Injectable Extended-Release Naltrexone (Vivitrol) FDA-Approved (First-Line) Long-acting depot μ \mu μ -opioid receptor antagonist 380 mg intramuscular (gluteal) injection once every 4 weeks First-line option when daily oral medication adherence is challenging. Bypasses first-pass hepatic metabolism. Same as oral naltrexone: concurrent opioid therapy, acute opioid withdrawal, acute hepatitis, decompensated cirrhosis. Injection site reactions (cellulitis, tissue necrosis).
Acamprosate (Campral) FDA-Approved (First-Line) Modulates central glutamatergic NMDA receptor hyperexcitability and enhances GABA neurotransmission; restores neurochemical equilibrium 666 mg PO three times daily (two 333 mg delayed-release tablets TID; total 1998 mg/day) First-line to maintain abstinence post-detoxification. Reduces post-cessation distress and negative affect. Safe in hepatic impairment / cirrhosis and in patients taking opioid analgesics . Contraindicated in severe renal impairment (CrCl < 30 mL/min < 30\text{ mL/min} < 30 mL/min ) . Dose reduce to 333 mg TID if CrCl 30–50 mL/min. High pill burden (6 tablets/day). Main side effect is mild diarrhea.
Disulfiram (Antabuse) FDA-Approved (Second-Line) Irreversible aldehyde dehydrogenase (ALDH) inhibitor; causes toxic accumulation of acetaldehyde upon ethanol ingestion 250 mg to 500 mg PO once daily Second-line aversive deterrent therapy. Effective only when administration is observed / supervised in highly motivated patients committed to absolute abstinence. Contraindicated in severe coronary artery disease, heart failure, psychosis, pregnancy, and concurrent metronidazole use . Severe reaction: flushing, nausea, projectile vomiting, diaphoresis, hypotension, chest pain, arrhythmias, collapse. Must be abstinent ≥ 12 \ge 12 ≥ 12 hours before start. Monitor LFTs (rare fatal hepatitis).
Topiramate (Topamax) Off-Label (Second-Line) Antagonizes AMPA/kainate glutamate receptors and enhances GABA-A transmission Titrated slowly: start 25 mg PO daily, titrate weekly by 25–50 mg to target 100–150 mg BID (total 200–300 mg/day) Decreases heavy drinking days and cravings; beneficial in co-occurring migraine, essential tremor, or weight gain. Cognitive slowing ("Dopamax"), sedation, paresthesias, metabolic acidosis (carbonic anhydrase inhibitor), nephrolithiasis, acute angle-closure glaucoma. Dose reduce in renal impairment.
Gabapentin (Neurontin) Off-Label (Second-Line) Modulates presynaptic voltage-gated calcium channels; increases brain GABA levels 300 mg to 600 mg PO three times daily (target 900–1800 mg/day) Reduces cravings, sleep disruption, and protracted subacute withdrawal anxiety. Favorable in patients with hepatic disease. Sedation, dizziness, ataxia, peripheral edema. Renally excreted (dose adjust for CrCl). Abuse/diversion potential; caution in co-occurring sedative/opioid use disorder.
Laboratory Markers of Chronic Alcohol Consumption
Laboratory biomarkers provide objective biological evidence to corroborate clinical history, assess end-organ hepatobiliary injury, monitor treatment adherence, and detect early relapse.
Master Table of Laboratory Biomarkers
Biomarker Diagnostic Threshold Pathophysiology / Mechanism Clinical Sensitivity & Specificity Kinetics / Normalization Timeline
AST : ALT Ratio Ratio > 2 : 1 > 2:1 > 2 : 1 (with AST usually < 300 – 500 U/L < 300–500\text{ U/L} < 300–500 U/L ) Hepatic pyridoxal 5'-phosphate (vitamin B6) deficiency impairs cytoplasmic ALT synthesis; alcohol-induced mitochondrial injury causes release of mitochondrial AST Specificity > 90 % > 90\% > 90% for alcoholic liver disease when ratio > 2 : 1 > 2:1 > 2 : 1 ; specificity exceeds 95% if ratio > 3 : 1 > 3:1 > 3 : 1 . Sensitivity ~50–70%. AST normalizes within 1 to 3 months of complete abstinence as hepatic inflammation resolves.
Serum GGT (Gamma-Glutamyl Transferase) Elevated above reference range (often > 50 – 100 U/L > 50–100\text{ U/L} > 50–100 U/L ) Ethanol directly induces hepatic microsomal enzyme synthesis and causes biliary canalicular membrane injury Sensitivity 70–85% for chronic heavy drinking ( > 4 – 5 >4–5 > 4–5 drinks/day for weeks). Specificity is modest (~60–70%) because GGT rises in NAFLD, biliary disease, and with enzyme inducers (phenytoin, carbamazepine). Half-life is 14 to 26 days. Returns toward baseline within 2 to 4 weeks of sustained abstinence. Excellent for monitoring early recovery.
MCV (Mean Corpuscular Volume) Macrocytosis (MCV 100 – 110 fL 100–110\text{ fL} 100–110 fL ) without folate/B12 deficiency Direct toxic effect of ethanol and acetaldehyde on developing erythroblast membrane lipid composition and DNA synthesis Sensitivity ~50–60%; specificity ~80–90% in the absence of hypothyroidism, reticulocytosis, myelodysplasia, or B12/folate deficiency. Reflects erythrocyte lifespan (120 days). Normalizes slowly over 2 to 4 months following cessation.
Urine Ethyl Glucuronide (EtG) & Ethyl Sulfate (EtS) Positive if ≥ 500 ng/mL \ge 500\text{ ng/mL} ≥ 500 ng/mL (standard cutoff) or ≥ 100 ng/mL \ge 100\text{ ng/mL} ≥ 100 ng/mL (sensitive cutoff) Minor direct non-oxidative hepatic Phase II metabolites formed by UDP-glucuronosyltransferase conjugation of ethanol Extremely high sensitivity (>95%) and specificity for recent alcohol consumption. Resistant to degradation. Standard cutoff avoids false positives from incidental hygiene exposures (hand sanitizers, mouthwash). Detectable in urine for 48 to 80 hours (up to 3–5 days after heavy binge drinking), long after ethanol has cleared the bloodstream. Ideal for forensic and abstinence-monitoring programs.
Carbohydrate-Deficient Transferrin (CDT) Elevated percentage of total transferrin ( > 1.7 – 2.0 % > 1.7–2.0\% > 1.7–2.0% ) Chronic heavy ethanol consumption ( > 50 – 80 g/day >50–80\text{ g/day} > 50–80 g/day for ≥ 2 \ge 2 ≥ 2 weeks) inhibits glycosyltransferases, producing transferrin molecules lacking sialic acid carbohydrate chains Highly specific (~90–95%) for sustained heavy drinking. Less sensitive for intermittent binge drinking. Not affected by mild nonalcoholic liver disease. Half-life of 10 to 14 days. Normalizes within 2 to 4 weeks of sustained abstinence.
Acute Alcohol Withdrawal Syndromes & Medical Safety
Family physicians must distinguish outpatient-treatable hazardous drinking from acute alcohol withdrawal requiring emergency hospitalization:
Clinical Spectrum of Alcohol Withdrawal
Minor Withdrawal (6 to 12 hours post-cessation) : Tremulousness (the "shakes"), insomnia, mild diaphoresis, palpitations, anxiety, headache, anorexia, mild tachycardia, and hypertension. Intact orientation.
Alcoholic Hallucinosis (12 to 24 hours post-cessation) : Visual, auditory, or tactile hallucinations with clear sensorium and intact orientation (vital signs are often normal; distinctly different from delirium tremens).
Withdrawal Seizures (12 to 48 hours post-cessation) : Generalized tonic-clonic seizures, typically singular or in a brief cluster (2 to 3 episodes). Treated acutely with IV benzodiazepines (e.g., lorazepam); standard anticonvulsants (phenytoin) are completely ineffective.
Delirium Tremens (DTs) (48 to 96 hours post-cessation) : Medical emergency with 5% to 15% mortality if untreated. Manifests as severe autonomic instability (severe hyperthermia, tachycardia > 120 bpm >120\text{ bpm} > 120 bpm , malignant hypertension, profuse drenching diaphoresis), global confusion, profound disorientation, and fluctuating delirium.
Inpatient vs. Outpatient Management Criteria
Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) :
Score < 10 < 10 < 10 : Mild withdrawal (eligible for supportive outpatient management if reliable caregiver and daily clinical check-in are present).
Score 10 – 19 10–19 10–19 : Moderate withdrawal (requires pharmacotherapy; consider inpatient admission if comorbidities exist).
Score ≥ 20 \ge 20 ≥ 20 : Severe withdrawal (mandates immediate inpatient admission, continuous cardiac telemetry, and aggressive symptom-triggered IV/oral benzodiazepines).
Wernicke Encephalopathy Prophylaxis : All patients entering alcohol detoxification must receive high-dose parenteral thiamine (100–500 mg daily) PRIOR TO OR CONCURRENT WITH any intravenous dextrose solutions . Administering glucose to a thiamine-deficient patient rapidly exhausts remaining thiamine pyrophosphate cofactors for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, precipitating acute irreversible Wernicke encephalopathy (confusion, ataxia, ophthalmoplegia/nystagmus) or Korsakoff psychosis (anterograde amnesia, confabulation).